30 results about "First line therapy" patented technology

The invention provides a metformin hydrochloride / voglibose sugar-lowering oral preparation composition and a preparation method thereof. The weight ratio of two main medicines is 8000:1-375:1, preferably 2500:1-625:1. Except for the main medicines, the composition also can further contain commonly used medicine accessories, such as a binder, a filling agent, a disintegrating agent, a lubricant, a flavoring agent, a wetting agent and a flow agent, and the obtained composition can be prepared into tablets, granules, soft and hard capsules, sustained and controlled release preparations, optimum enteric-coated tablets, enteric-coated granules and enteric-coated soft and hard capsules by conventional methods. The composition provided by the invention has action mechanism complementation of the main medicines, multiple target points, good compliance of patients, and the like. The sugar-lowering oral preparation composition can be used for the first-line therapy of type 2 diabetes, or can be used for second-line therapy under the condition that the metformin hydrochloride or sulfonylurea medicines fail to singly and effectively control blood sugar; and the sugar-lowering oral preparation composition is especially suitable for the therapy of diabetic patients suffering from latent autoimmune diabetes in adults (LADA) and hyperinsulinemia.

The present invention relates to a method to assist in the determination of therapy for a patient suffering from Barrett's oesophagus, especially where first-line therapy has been unsuccessful and when dysplasia has been diagnosed. The method comprises the use of an imaging agent comprising a vector which targets (a) Her2, (b) cMet, (c) guanylyl cyclase or (d) IGF1R. The imaging agent is suitable for radioisotope or optical imaging in vitro or preferably in vivo.

The invention relates to the field of recombinant antibodies for use in human cancer therapy. More specifically the invention provides the use of an antibody composition with two distinct non-overlapping binding specificities to human EGFR. The antibody composition is effecting in treating cancer following treatment with other anti-EGFR antibodies, whether the cancer shows progression during or following the prior treatment or not. The antibody composition can also be used for repeated treatment of recurrent tumors following first-line therapy with the antibody composition of the invention, as the composition does not lead to selection of resistant tumors. A further therapeutic use is the use of an antibody composition of the invention for treatment of cancer that is resistant to known anti-EGFR antibodies.

An oncolytic virus is for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelial carcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patientswith no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / orcancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panelof three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

An oncolytic virus for use in a method of treating or preventing cutaneous squamous cell carcinoma (CSCC), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), small cell lung cancer (SCLC), advanced recurrent head and neck cancer, squamous cell carcinoma of the head and neck (SCCHN), nasopharyngeal carcinoma (NPC), hepatocellular carcinoma (HCC), anal cancer, colorectal cancer (CRC), basal cell carcinoma (BCC), Merkel cell carcinoma, appendiceal carcinoma, sarcoma of the skin, recurrent melanoma after surgery, advanced or metastatic urothelialcarcinoma, liver metastases, microsatellite instability high cancer (MSI-H), mixed advanced solid tumors, virally caused cancer, locoregionally advanced cancer, pediatric cancer, cancer in patients with no or minimal pre-existing anti-cancer immunity, cancer as first line therapy, cancer in previously treated patients, cancer in patients who have not received checkpoint blockade therapy, and / or cancer in patients who have received checkpoint blockade therapy, wherein the oncolytic virus: is, or is derived from, a clinical isolate which has been selected by comparing the abilities of a panel of three or more clinical isolates of the same viral species to kill tumor cells of two or more tumor cell lines in vitro and selecting a clinical isolate which is capable of killing cells of two or more tumor cell lines more rapidly and / or at a lower dose in vitro than one or more of the other clinical isolates in the panel; comprises (i) a fusogenic protein-encoding gene; and (ii) an immune stimulatory molecule or an immune stimulatory molecule-encoding gene; comprises (i) a GM-CSF-encoding gene; and (ii) an immune co-stimulatory pathway activating molecule or an immune co-stimulatory pathway activating molecule-encoding gene; and / or comprises a gene encoding a CTLA-4 inhibitor.

The present invention provides compositions and methods for treating cancer in a patient. In one embodiment, the method comprises a first-line therapy comprising administering to a patient in need thereof a genetically modified T cell expressing a CAR wherein the CAR comprises an antigen binding domain, a transmembrane domain, a costimulatory signaling region, and a CD3 zeta signaling domain and monitoring the levels of cytokines in the patient post T cell infusion to determine the type of second-line of therapy appropriate for treating the patient as a consequence of the presence of the CART cell in the patient.

The invention discloses CDK4 / 6 inhibitor and HER2 inhibitor combination for gastric cancer treatment and application of a CDK4 / 6 inhibitor and a HER2 inhibitor to preparation of a composition for treatment of HER2 positive gastric cancer patients with drug tolerance. In gastric cancer clinical research history, the patients with drug tolerance after first-line treatment are slightly benefited no matter which drug / scheme is adopted. Excellent benefits achieved by use of the treatment combination are rare, and the treatment combination is put forward for the first time on the basis of preclinical study and verified through clinical researches on patients and is a landmark major breakthrough in the field of gastric cancers.

The invention discloses application of Tipranavir in preparation of a cancer treatment drug for killing tumor stem cells and tumor cells, and relates to the technical field of medicines. The inventionfurther discloses a cancer treatment drug. The drug can kill the tumor stem cells and the tumor cells; the drug takes the Tipranavir as a main active component and contains a pharmaceutically acceptable carrier. The invention provides the Tipranavir for the first time, and the Tipranavir can be used for preparing the anti-cancer drug for killing the tumor stem cells and the tumor cells; the anti-gastric cancer effect of the Tipranavir is obviously better than that of an existing gastric cancer first-line treatment drug (5-FU and cisplatin are combined); the Tipranavir has no obvious toxic side effect and the toxic side effect is obviously smaller than that of the gastric cancer first-line treatment drug (5-FU and cisplatin are combined); a novel drug and scheme are provided for tumor treatment of targeted tumor stem cells and healing of tumors; and the Tipranavir has important meanings on improvement of the tumor treatment effect and improvement of the living quality of patients.

The invention relates to a method of pre-surgical risk stratification of a prostate cancer subject, comprising determining a gene expression profile for phosphodiesterase 4D variant 7 (PDE4D7) in a biological sample obtained from the subject, determining an expression based risk score for the subject based on the gene expression profile, and determining a pre-surgical prognostic risk score for thesubject based on the expression based risk score and pre-surgical clinical variables of the subject. This may allow for an improved stratification of the subject in a pre-surgical setting that may result in better primary treatment decisions. For instance, the pre-surgical prognostic risk score may allow to make better recommendations on whether to select active surveillance vs. active intervention, e.g., radical prostatectomy, for certain sub-populations of prostate cancer patients.

The invention specifically relates to the application of the extract of cassia twigs and rhizomes in the preparation of medicines for treating adenomyosis. Aiming at the current situation that there is no specific drug for the treatment of adenomyosis and it is difficult to cure it, the purpose of the present invention is to screen the extracts with anti-adenomyosis activity from the drugs commonly used in clinical practice to promote blood circulation, remove blood stasis, soothe the liver and regulate qi. It helps to clarify the treatment mechanism of adenomyosis and provide corresponding drugs for the clinical treatment of adenomyosis. The research of the present invention provides the extracts of cinnamon twig, chrysanthemum, and jerky root, and combined extracts, and verifies that the above-mentioned extracts have an inhibitory effect on the ectopic lesion cells of adenomyosis. Further, it also provides the above-mentioned extracts that inhibit Mechanism of focal tissue. The extracts of cassia twig, chrysanthemum, japonicus and combined extracts provided by the present invention are expected to become active ingredients for the clinical treatment of adenomyosis, and are of great significance to the development of first-line therapeutic drugs.

Described are methods for assessing recurrence status in a breast cancer patient that include assaying a biological sample from the patient for a level of a biomarker selected from such as S100β or HOX-C1I, where positive detection of one or both of the biomarkers indicates a positive recurrence status. The method can be used for prognosis of poor disease free survival in a breast cancer patient, where positive detection of one or both of the biomarkers indicates poor disease survival. The method may also be used for diagnosis of recurrence, where positive detection of circulating S100β is a diagnostic variable of recurrence. The method of diagnosis is carried out on a patient who is undergoing first line therapy and / or a patient who has had surgery to remove a primary breast tumour.

The invention discloses the use of Tipranavir in the preparation of cancer treatment drugs for killing tumor stem cells and tumor cells, and relates to the technical field of medicine. The invention also discloses a cancer treatment drug, which can kill tumor stem cells and tumor cells; the drug uses Tipranavir as the main active ingredient and contains a pharmaceutically acceptable carrier. The present invention provides for the first time that Tipranavir can be used to prepare an anticancer drug that kills tumor stem cells and tumor cells. Its anti-gastric cancer effect is significantly better than the existing first-line treatment drug for gastric cancer (combined use of 5-FU and cisplatin), and has no obvious side effects. The toxic and side effects are significantly less than the first-line treatment of gastric cancer (5-FU and cisplatin combined), which will provide new drugs and solutions for tumor treatment targeting tumor stem cells and cure tumors, and have a positive effect on improving the effect of tumor treatment and the quality of life of patients. important meaning.

The invention provides an optimized adult first-line AIDS (Acquired Immune Deficiency Syndrome) antiviral therapy program. Concretely, the therapy program of the invention includes (a) a first stage: employing the stavudine-containing (D4T) program to treat for a period of time (such as 4-12 months); and (b) a second stage: replacing stavudine with zidovudine (AZT) for treatment. The therapy program of the invention not only gets a good therapeutic effect, but also can reduce the toxic and side effects of D4T and AZT, and is an equivalent and relatively safe first-line therapy program.

The invention belongs to the field of biomedicine and specifically discloses that Crizo combined with Dox synergistically induces cancer cell death. Compared with single-drug treatment, the combination of the two drugs increased cell death by at least 50%, which was much stronger than the combination of sorafenib and Dox, the first-line treatment drugs for advanced liver cancer, in inducing apoptosis of liver cancer cells. The present invention clarifies the mechanism of the above effects from the cellular level, and reveals that Crizo combined with Dox can overcome the resistance to chemotherapeutic drugs by inhibiting the expression of MDR1 and inducing autophagic cell death. Combined with in vivo experiments, it shows that Crizo combined with Dox can effectively inhibit tumor growth in animal models with less toxic side effects, which provides a potential therapeutic strategy for the treatment of cancer, especially advanced liver cancer.

The invention discloses a traditional Chinese medicine composition for treating allergic rhinitis and application thereof. The traditional Chinese medicine composition is prepared from eugenol and total saponins of radix astragali seu hedysari. A nasal spray prepared from the traditional Chinese medicine composition can be used for treating allergic rhinitis through local nasal administration, has an experimental drug effect superior to that of a first-line treatment drug, takes effect quickly, can take effect after being sprayed for 1-3 minutes, reduces nasal obstruction, running nose and the like, has no side effect, and can achieve a radical treatment effect on part of people. After the nasal spray is administrated to rats, the results show that the nasal spray for the corydalis bungeana group is superior to triamcinolone acetonide (positive control group) in the aspects of reducing a main allergic medium IgE, reducing nasal mucous membrane secretory mucoprotein MUC5AC and improving rhinitis pathology, the eugenol and the total saponins of radix astragali seu hedysari are matched to play a synergistic effect, and the effect exceeds that of single eugenol and single total saponins of radix astragali seu hedysari.

The invention provides methods of treatment, pharmaceutical compositions, systems and kits appropriate for first line and / or adjunct therapy with antivenom using at least one active component, in some instances at least two active components and in other instances no more than two active components selected from the group consisting of a selective secretory PLA2 inhibitor (sPLA2 or PLA2 inhibitor), a metalloproteinase inhibitor, a serine protease inhibitor, antivenom, one or more acetylcholinesterase inhibitors or a nAChR agonist paired with a mAChR antagonist, a NMDA receptor antagonist and a spreading factor inhibitor to treat a subject who suffers from an envenomation, preferably at the time of envenomation and often within a period of less than about an hour after an envenomation or 6 hours after an envenomation and throughout the course of treatment at time with or without antivenom as an adjunct therapy after an envenomation by, for example, a snake or invertebrate.

A low dose antidiabetic pharmaceutical formulation is provided, especially adapted for treating Type II diabetes in drug naive patients, which includes a combination of metformin (employed in a reduced amount (less than 800 mg metformin per day) compared to that employed in generally accepted medical practice) and at least one other antidiabetic agent such as a sulfonyl urea, for example, glyburide, which combination provides at least about substantially equivalent efficacy in treating diabetes in drug naive patients, as do antidiabetic formulations containing metformin employed in dosages prescribed in generally accepted medical practice for first line therapy in treating diabetes, but with substantially reduced side effects, such as hypoglycemia and / or gastrointestinal distress. A method for treating diabetes in drug naive human patients is also provided employing the above formulation to reduce insulin resistance and / or post-prandial glucose excursion and / or hemoglobin 1Ac, and / or increase post-prandial insulin, thereby treating the diabetes.